MELBOURNE, Australia, April 02, 2025 (GLOBE NEWSWIRE) -- Telix Pharmaceuticals Limited (ASX: TLX; NASDAQ: TLX, Telix, the Company) today announces that a first patient has been dosed in the Phase 1 ZOLAR1 trial of TLX300-CDx (89Zr-olaratumab) in patients with advanced, metastatic...Read more
POTOMAC, MARYLAND / ACCESS Newswire / April 1, 2025 / IGC Pharma, Inc. (NYSE American:IGC) today announced the expansion of its Phase 2 clinical trial, CALMA, evaluating IGC-AD1 for the treatment of agitation in Alzheimer's dementia, to MIND Institute at Miami Jewish Health in...Read more
The Independent Data Monitoring Committee (IDMC) has recommended to continue study as planned as there are no safety concerns seen in the data reviewed Interim results demonstrate GRI-0621 to be safe and well-tolerated in the first 12 patients evaluated Interim biomarker data...Read more
FDA aligned on plan to initiate parallel Phase 2 trials of rademikibart in patients with moderate-to-severe asthma or COPD experiencing an acute exacerbation Expect to initiate both trials in Q2 2025 SAN DIEGO, April 01, 2025 (GLOBE NEWSWIRE) -- Connect Biopharma Holdings Limited (Nasdaq:...Read more
PDUFA target action date is July 28, 2025 WALTHAM, Mass., April 01, 2025 (GLOBE NEWSWIRE) -- Apellis Pharmaceuticals, Inc. (Nasdaq: APLS) today announced that the U.S. Food and Drug Administration (FDA) has accepted and granted Priority Review designation of the supplemental New Drug...Read more
WAYNE, Pa., April 01, 2025 (GLOBE NEWSWIRE) -- Teleflex Incorporated (NYSE: TFX), a leading global provider of medical technologies, today announced FDA 510(k) clearance of the AC3 Range™ Intra-Aortic Balloon Pump (IABP). Leveraging the patented technology of the AC3 Optimus™ IABP, the AC3 Range™...Read more
Immix Biopharma is a clinical-stage biopharmaceutical company pioneering a novel class of CAR-T cell therapies and Tissue-Specific Therapeutics targeting oncology and immuno-dysregulated diseases with >75 patients treated to-date. The company's lead cell therapy asset is NXC-201 in multiple myeloma...
CLICK TO LEARN MORE| Company | Change | Last Trade |
|---|---|---|
| Nutex Health | 24.37 51.82 | $71.40 |
| Aclarion | 10.78 1,437.33 | $11.53 |
| Penumbra | 3.72 1.39 | $271.13 |
| Chemed | 3.24 0.53 | $618.56 |
| OpGen | 2.22 116.84 | $4.12 |
| iRhythm Technologies | 2.20 2.10 | $106.88 |
| AbbVie | 2.19 1.07 | $206.27 |
| Teleflex | 2.11 1.53 | $140.30 |
| Cigna | 2.00 0.61 | $331.00 |
| Pro-Dex | 1.82 3.67 | $51.40 |
| Addus HomeCare | 1.63 1.68 | $98.93 |
| LeMaitre Vascular | 1.26 1.50 | $85.16 |
| Repligen | 1.26 0.99 | $128.50 |
| Acadia Healthcare | 1.24 4.32 | $29.93 |
| ReShape Lifesciences | 1.23 341.05 | $1.59 |
| ClearPoint Neuro | 1.20 10.09 | $13.09 |
| Zai Lab | 1.15 3.18 | $37.29 |
| AtriCure | 1.10 3.41 | $33.36 |
| Company | Volume | Last Trade |
|---|---|---|
| bioAffinity Technologies | 484,676,612 | $1.07 |
| Sharps Technology | 330,440,731 | $0.03 |
| ReShape Lifesciences | 242,131,070 | $1.59 |
| Petros Pharmaceuticals | 65,781,376 | $0.08 |
| Pfizer | 52,227,334 | $24.55 |
| Hepion Pharmaceuticals | 49,959,628 | $0.49 |
| Geron | 31,074,758 | $1.48 |
| Lexicon Pharmaceuticals | 26,875,158 | $0.49 |
| Ocean Biomedical | 22,842,282 | $0.05 |
| Compass Therapeutics | 22,126,087 | $2.23 |
| Johnson & Johnson | 19,634,428 | $153.39 |
| Humacyte | 17,913,198 | $1.49 |
| Recursion | 16,708,540 | $5.10 |
| Intra-Cellular Therapies | 15,258,368 | $131.87 |
| Veru | 14,956,698 | $0.66 |
| Sangamo Therapeutics | 13,633,448 | $0.57 |
| Merck | 13,183,294 | $87.12 |
| Bristol-Myers Squibb | 13,034,568 | $59.55 |
| GRI Bio | 11,962,152 | $2.04 |
Amneal Pharmaceuticals is a fully-integrated essential medicines company. We make healthy possible through the development, manufacturing, and distribution of generic and specialty pharmaceuticals. The Company has a diverse portfolio of over 250 products in its Generics segment and is expanding across...
CLICK TO LEARN MORE
Recursion is a clinical stage TechBio company leading the space by decoding biology to industrialize drug discovery. Enabling its mission is the Recursion OS, a platform built across diverse technologies that continuously expands one of the world’s largest proprietary biological and chemical datasets...
CLICK TO LEARN MORE
C4 Therapeutics is pioneering a new class of small-molecule drugs that selectively destroy disease-causing proteins via degradation using the innate machinery of the cell. This targeted protein degradation approach offers advantages over traditional drugs, including the potential to treat a wider range of diseases...
CLICK TO LEARN MORE
Viking Therapeutics is a clinical-stage biopharmaceutical company focused on the development of novel first-in-class or best-in-class therapies for the treatment of metabolic and endocrine disorders, with three compounds currently in clinical trials. Viking’s research and development activities leverage...
CLICK TO LEARN MORE
